Article
Immunology
Priyanka Devi-Marulkar, Carolina Moraes-Cabe, Pascal Campagne, Beatrice Corre, Aida Meghraoui-Kheddar, Vincent Bondet, Alba Llibre, Darragh Duffy, Elisabeth Maillart, Caroline Papeix, Sandra Pellegrini, Frederique Michel
Summary: This study investigated the blood signatures associated with the efficacy of IFN beta treatment in RRMS patients. Non-responders showed specific changes in immune cells and approximately 600 immune-related genes, as well as specific HLA-DQB1 genotypes, suggesting potential resistance to therapeutic IFN beta.
FRONTIERS IN IMMUNOLOGY
(2021)
Article
Clinical Neurology
Nicolas Fissolo, Pascal Benkert, Jaume Sastre-Garriga, Neus Mongay-Ochoa, Andreu Vilaseca-Jolonch, Sara Llufriu, Yolanda Blanco, Harald Hegen, Klaus Berek, Francisco Perez-Miralles, Konrad Rejdak, Luisa M. Villar, Enric Monreal, Roberto Alvarez-Lafuente, Onder K. Soylu, Ahmed Abdelhak, Franziska Bachhuber, Hayrettin Tumani, Sergio Martinez-Yelamos, Antonio J. Sanchez-Lopez, Antonio Garcia-Merino, Lucia Gutierrez, Tamara Castillo-Trivino, Jan Lycke, Igal Rosenstein, Roberto Furlan, Massimo Filippi, Nieves Tellez, Lluis Ramio-Torrenta, Jan D. Lunemann, Heinz Wiendl, Sara Eichau, Michael Khalil, Jens Kuhle, Xavier Montalban, Manuel Comabella
Summary: This study aimed to investigate the potential of serum biomarker levels in predicting disability progression in patients with primary progressive multiple sclerosis (PPMS). The study found that levels of neurofilament light chain (sNfL), glial fibrillar acidic protein (sGFAP), and chitinase 3-like 1 (sCHI3L1) were associated with changes in the Expanded Disability Status Scale (EDSS) over different time periods.
JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY
(2023)
Article
Clinical Neurology
Kristin Galetta, Chinmay Deshpande, Brian C. Healy, Bonnie Glanz, Marina Ziehn, Shrishti Saxena, Anu Paul, Fermisk Saleh, Mikaela Collins, Patricia Gaitan-Walsh, Paola Castro-Mendoza, Howard L. Weiner, Tanuja Chitnis
Summary: In practice, serum neurofilament light is associated with health outcomes and healthcare utilization in multiple sclerosis patients.
ANNALS OF CLINICAL AND TRANSLATIONAL NEUROLOGY
(2021)
Article
Clinical Neurology
Paolo Immovilli, Eugenia Rota, Nicola Morelli, Donata Guidetti
Summary: In recent years, the treatment of pediatric multiple sclerosis has been subject to increasing debate due to limited understanding of treatment strategies and drug options. While some data suggest the potential benefits of immunomodulatory drugs, more research and clinical trials are needed to determine the optimal treatment approach for pediatric MS. The PARADIGMS trial showed promising results with fingolimod compared to interferon beta-1a in reducing relapse rates, but further studies are necessary to confirm these findings and improve treatment outcomes for young patients with MS.
NEUROLOGICAL SCIENCES
(2021)
Article
Immunology
Undine Proschmann, Rocco Haase, Hernan Inojosa, Katja Akgun, Tjalf Ziemssen
Summary: This study observed women treated with natalizumab during pregnancy and lactation, finding that most patients did not experience disease activity during gestation and postpartum. Natalizumab concentration in breastmilk was low but detectable sNfL levels were present in most samples.
FRONTIERS IN IMMUNOLOGY
(2021)
Article
Clinical Neurology
Manuel Comabella, Jaume Sastre-Garriga, Pere Carbonell-Mirabent, Nicolas Fissolo, Carmen Tur, Sunny Malhotra, Deborah Pareto, Francesc X. Aymerich, Jordi Rio, Alex Rovira, Mar Tintore, Xavier Montalban
Summary: This study found that serum neurofilament light chain (sNfL) levels can be used as a prognostic biomarker for future long-term disability progression in patients with progressive multiple sclerosis (MS).
JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY
(2022)
Article
Clinical Neurology
Brit Ellen Rod, Oivind Torkildsen, Kjell-Morten Myhr, Lars Bo, Stig Wergeland
Summary: Our study found minimal transfer of rituximab into breast milk in nursing mothers, and the levels of rituximab in infant serum were difficult to detect. The B cell counts in infants were unaffected.
JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY
(2023)
Article
Medicine, General & Internal
Chao-Wen Cheng, Kam-Tsun Tang, Wen-Fang Fang, Ting- Lee, Jiunn-Diann Lin
Summary: In this study, the association between serum IFN-beta levels and AITD was explored in an ethnic Chinese population. It was found that serum IFN-beta levels were lower in HT patients and correlated with TSHRA beta and BAFF levels, but the correlations were gender-specific. Larger studies are needed to confirm these findings.
ARCHIVES OF MEDICAL SCIENCE
(2022)
Article
Medical Laboratory Technology
Sepideh Moharami, Alireza Nourazarian, Masoud Nikanfar, Delara Laghousi, Behrouz Shademan, Omid Joodi Khanghah, Fatemeh Khaki-Khatibi
Summary: This study found significantly lower levels of orexin-A and TGF-beta, and significantly higher levels of leptin in MS patients compared to the control group. Additionally, there was no significant relationship between the BMI and the serum levels of orexin-A, TGF-beta, and leptin in MS patients.
JOURNAL OF CLINICAL LABORATORY ANALYSIS
(2022)
Article
Chemistry, Multidisciplinary
Luis F. Gonzalez, Eric Acuna, Gabriel Arellano, Paola Morales, Paula Sotomayor, Felipe Oyarzun-Ampuero, Rodrigo Naves
Summary: A new delivery system of IFN-β nanoparticles via intranasal administration was developed to improve clinical symptoms and control neuroinflammation in an experimental model of multiple sclerosis, showing potential effectiveness, non-invasiveness, and cost-effectiveness as a therapy for MS.
JOURNAL OF CONTROLLED RELEASE
(2021)
Article
Immunology
Ide Smets, Teresa Prezzemolo, Maya Imbrechts, Klara Mallants, Tania Mitera, Stephanie Humblet-Baron, Benedicte Dubois, Patrick Matthys, Adrian Liston, An Goris
Summary: The study indicates that both fingolimod and interferon-beta induce BAFF protein and mRNA expression, leading to a shift in the B cell pool towards a regulatory phenotype. Specifically, BAFF protein correlated with an increase in transitional B cells, decrease in switched B cells, and reduction in B cell-surface BAFF-R expression. However, BAFF does not directly influence the expression of immunoregulatory cytokines IL-10 and IL-35.
FRONTIERS IN IMMUNOLOGY
(2021)
Article
Medicine, General & Internal
Kriste Kaikaryte, Greta Gedvilaite, Renata Balnyte, Ingrida Uloziene, Rasa Liutkeviciene
Summary: The study investigated the association between SIRT1 gene variations and multiple sclerosis in the Lithuanian population, showing potential differences in gender and age. Lower serum SIRT1 levels were also found in MS patients compared to healthy controls.
Article
Clinical Neurology
Carlos Camara-Lemarroy, Claudia Silva, Jit Gohill, V. Wee Yong, Marcus Koch
Summary: In this cohort of patients with inactive PPMS, HCQ treatment attenuated the increase of NfL and GFAP after 6 months of treatment and up to 18 months of follow-up, suggesting a treatment effect of HCQ over these biomarkers. RNFL thickness, a marker of neuroaxonal atrophy, was associated with disability worsening and should be explored further as a prognostic marker in this population.
EUROPEAN JOURNAL OF NEUROLOGY
(2023)
Article
Clinical Neurology
Arabella Buchmann, Lukas Pirpamer, Daniela Pinter, Margarete Voortman, Birgit Helmlinger, Alexander Pichler, Aleksandra Maleska Maceski, Pascal Benkert, Gerhard Bachmaier, Stefan Ropele, Markus Reindl, David Leppert, Jens Kuhle, Christian Enzinger, Michael Khalil
Summary: This study findings suggest that elevated levels of sNfL have a significant impact on brain volume changes and can indicate disease progression in pwMS over a short-term period.
EUROPEAN JOURNAL OF NEUROLOGY
(2023)
Article
Clinical Neurology
Marja Niiranen, Aleksi Kontkanen, Olli Jaaskelainen, Hanna-Mari Tertsunen, Tuomas Selander, Paivi Hartikainen, Nadine Huber, Eino Solje, Annakaisa Haapasalo, Tarja Kokkola, Tarja Lohioja, Sanna-Kaisa Herukka, Sakari Simula, Anne M. Remes
Summary: The study found significantly elevated serum GFAP levels in both BRRMS and ARRMS patients compared to healthy controls, with no significant differences between BRRMS and ARRMS. There were also no significant differences in serum NfL levels among the groups.
MULTIPLE SCLEROSIS AND RELATED DISORDERS
(2021)
